Hi Hodgsop, Nice pick up, and the media attention around...

Hi Hodgsop,

Nice pick up, and the media attention around Mesoblast a copule of years ago was not just in Australia, but in the US as well. See below:



Although these stories were run run a couple of years ago across two different continents... it does highlight two important things for Mesoblast:

1. There is an un-met need and Mesoblast have a product in the making that will be regarded as the 'holy grail' of lower back-pain treatment.

2. It takes a lot of money and a very very long time from inception, research, development, trial, trail again, and trial again, to finally filing for approval for commercial sale. We are talking almost a decade from inception to a product such as MPC-06-ID is made ready for commercial sale. This is a significant barrier to entry and Mesoblast has no other known competitor that can offer the same level of efficacy (or even close) for this un-met need.

When the programs were made around 2 years ago, we were getting results for phase 2 trials. We are now almost 2 years on and the first Phase 3 trials will be commencing end of 2016 (have been recruiting since Mar15), with a finish date of December 2017 (12 month effectiveness trial).

See below for details of the trial.

Phase 3 trials MPC-06-ID

The pipe-line for MSB has always been amazing, but what is exciting is that the pipe-line is not only growing, but the value inflextion points of existing products are getting very very close. With CHF phase 3 trial IA results this quarter, and the updated timetable to be released. CHF could be stopped early if overwhelming efficacy is demonstrated ... so watch this space!